Sanofi's Dupixent Triumphs in Phase 3 COPD Trial, Expands Potential Use for 'Smoker's Lung'
TL;DR Summary
The inflammation-targeting therapy Dupixent, developed by Sanofi and Regeneron Pharmaceuticals, has shown success in a Phase 3 trial for patients with chronic lung disease COPD. If approved, it would be the first biologic treatment for COPD, potentially expanding the market for the blockbuster medicine.
- Sanofi, Regeneron therapy Dupixent succeeds in Phase 3 COPD trial STAT
- Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win Reuters
- Sanofi's Dupixent Shows Strong Efficacy in Second Lung Trial Bloomberg
- Bioscience job market is upside down - STAT STAT
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
65%
127 → 44 words
Want the full story? Read the original article
Read on STAT